| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.
|
Br J Clin Pharmacol
|
2007
|
0.99
|
|
2
|
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
|
Clin Pharmacokinet
|
2007
|
0.93
|
|
3
|
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
|
J Clin Pharmacol
|
2007
|
0.87
|
|
4
|
Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
|
J Clin Pharmacol
|
2007
|
0.83
|
|
5
|
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
|
Curr Med Res Opin
|
2007
|
0.82
|
|
6
|
Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.
|
J Clin Pharmacol
|
2007
|
0.80
|
|
7
|
Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
|
Curr Med Res Opin
|
2009
|
0.77
|
|
8
|
Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
|
J Clin Pharmacol
|
2011
|
0.75
|